Parkinson's Disease Drugs Market Size, Share & Trends Analysis Report By Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, Other Mechanisms of Action) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Parkinson's Disease Drugs Market Size

The global parkinson's disease drugs market size was valued at USD 5.92 billion in 2025 and is projected to grow from USD 6.13 billion in 2026 to USD 8.10 billion by 2034, registering a CAGR of 3.55% during the forecast period from 2026 to 2034. Europe dominated the parkinson's disease drugs market with a market share of 34.2% in 2025.

Parkinson's Disease is a nervous system disorder that impairs movement control. Parkinson's Disease is caused by the death or destruction of nerve cells (neurons) in the brain's substantia nigra (SN) region. Often, the problem develops gradually and gets worse over time. The few signs of Parkinson's Disease include trembling, muscle rigidity, difficulty walking, maintaining bodily balance, and coordination. Increasing pharmacological approvals for treating Parkinson's Disease will stimulate market expansion during the anticipated time frame.

Mechanism of Action

The market is bifurcated into dopamine agonists, anticholinergics, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of action. The carbidopa-levodopa segment is the highest contributor to the market and is estimated to grow at a CAGR of 7.42% during the forecast period. Levodopa is peripherally converted to dopamine by the enzyme amino acid decarboxylase (dopa decarboxylase), which is inhibited by carbidopa. For the treatment of PD, the mechanism of action is well known. Carbidopa stops nausea and delays the early conversion of levodopa into dopamine in the bloodstream, allowing more of it to reach the brain. Most medications are administered orally, although different pharmaceutical companies have adjusted the dosage in tablet form by making them extended-release, film-coated, and disintegrating. Among the well-known medications discovered are those sold under Sinemet, CR, Parcopa, Rytary, and Duopa. For the treatment of motor complaints, combination therapy is one of the best. Additionally, it is anticipated that increased new product launches and drug approvals will fuel growth in the future.

Dopamine agonists (DA agonists) are one of the primary drugs frequently used to treat Parkinson's Disease symptoms because they have proven to be successful in lowering the motor fluctuations seen in many Parkinson's patients. Agonists of dopamine function by imitating dopamine. They bind to and activate dopamine receptors, proteins on the neurons, which relieve symptoms, especially motor symptoms such as rigidity, poor balance, tremors, and lack of spontaneous movement. Ergoline and non-ergoline agonists are two categories of dopamine agonists. First-generation drugs include ergoline agonists like bromocriptine, cabergoline, and pergolide, whereas second-generation drugs include pramipexole, ropinirole, rotigotine, and apomorphine. However, dopamine agonists have several side effects, such as nausea, hallucinations, sleep attacks, dyskinesia, dizziness, orthostatic hypotension, etc., which may limit their use and restrain the market's expansion.

Request Customizationto receive a tailored report.

Speak to an Analystto discuss market opportunities.

Regional Insights

Europe is the most significant revenue contributor and is expected to grow at a CAGR of 4.36% during the forecast period. Most of the disease's victims are discovered to be elderly individuals since, according to the Fondation de France, one in three French people will likely have PD by the year 2050, and one in five is over 60. The market has a wide variety of new medications, contributing to increased demand among French consumers. In a groundbreaking Phase II clinical trial for the medicine ondansetron, Parkinson's UK collaborated with UCL and intended to invest GBP 1 million. This trial will determine Ondansetron's efficacy and safety as a treatment. To determine whether inhibiting the immune system can halt the progression of Parkinson's Disease, the University of Cambridge researchers are utilizing individuals with recently diagnosed Parkinson's Disease in a Phase II clinical trial of azathioprine. The amount of research has been steadily rising, helping the market as a whole.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific Parkinson's Disease Drugs Market Trends

Asia-Pacific is expected to grow at a CAGR of 4.64% during the forecast period. Britannia Pharmaceuticals, a specialty pharmaceutical business with headquarters in the U.K., introduced Apomorphine in India in collaboration with Vikram Hospital in Bengaluru. For more than 15 years, apomorphine injections and infusion pumps have been widely used in the West to treat Parkinson's Disease. Additionally, most Indian organizations work to raise P.D. knowledge among the populace there. For instance, World Parkinson's Day is observed by the PDMDS (Parkinson's Disease and Movement Disorder Society), an all-India registered charitable organization. This means that the market is anticipated to expand throughout the forecast period due to rising product approvals and rising community awareness. Parkinson's Disease patients have been reported to benefit from using Zhichan, a traditional Chinese treatment. Various active ingredients in it may have therapeutic benefits for Parkinson's Disease. These complementary treatments could, however, impede the development of P.D. medications. Azilect, a novel drug created by Lundbeck and Teva to treat P.D., was introduced in Shanghai. With the introduction of Azilect, Chinese medical professionals and PD patients now have a new therapy choice that can meet their demands and enhance their quality of life.

One of the biggest markets for Parkinson's medications is determined to be in the United States. Nearly one million Americans are estimated to have Parkinson's Disease (PD), according to the Parkinson's Foundation. Additionally, P.D. is diagnosed in about 60,000 Americans each year. As a result, the prevalence of Parkinson's Disease rises with age, although only around 4% of those with the disease are identified before age 50. According to the Parkinson's Foundation, Parkinson's Disease is the 14th most common cause of mortality in the United States and the second-most prevalent neurological disease after Alzheimer's. The Nourianz (istradefylline) tablets have been given the go-ahead by the U.S. Food and Drug Administration as a supplement to levodopa/carbidopa in the treatment of adult Parkinson's Disease (P.D.) patients who are having "off" periods. When a patient's meds aren't working correctly, they experience an "off" episode, which worsens their PD symptoms, including tremors and difficulties walking.

Brazil has authorized the distribution of cannabis-based pharmaceuticals to patients with valid prescriptions. The Brazilian Health Regulatory Agency claims that the regulation will permit the production of such items in a lab (Anvisa). Since reporting of P.D. is not required in Brazil, its prevalence can only be approximated there. According to estimates, there are 220,000 patients, and according to specific worldwide research, that number is predicted to more than double by 2030. Therefore, it is anticipated that rising disease prevalence will fuel market expansion.

List of Key and Emerging Players in Parkinson's Disease Drugs Market